Sugi Predict

Sugi Predict / Targets / CSNK1G2

CSNK1G2

Casein kinase I isoform gamma-2 · P78368 · CSNK1G2 on Sugi Atlas →

44,736 patent compounds predicted against CSNK1G2, 32,690 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL232042 SCHEMBL232042 1.00 5/20
SCHEMBL234334 SCHEMBL234334 1.00 5/20
SCHEMBL264696 SCHEMBL264696 0.39 5/20
SCHEMBL90887 SCHEMBL90887 0.49 4/20
SCHEMBL90935 SCHEMBL90935 0.49 4/20
SCHEMBL69655 SCHEMBL69655 0.45 4/20
Linifanib Linifanib (SCHEMBL93804) 1.00 3/20
SCHEMBL299518 SCHEMBL299518 0.76 3/20
SCHEMBL65790 SCHEMBL65790 0.52 3/20
Hydrochloric Acid Hydrochloric Acid (SCHEMBL58421) 0.52 3/20
SCHEMBL239188 SCHEMBL239188 0.48 3/20
SCHEMBL319631 SCHEMBL319631 0.43 3/20
Sunitinib Sunitinib (SCHEMBL8081) 1.00 2/20
Sunitinib Sunitinib (SCHEMBL8082) 1.00 2/20
Seliciclib Seliciclib (SCHEMBL94728) 1.00 2/20
(Rs)-Roscovitine (Rs)-Roscovitine (SCHEMBL172593) 1.00 2/20
Sunitinib Sunitinib (SCHEMBL18648) 0.92 2/20
Sunitinib Sunitinib (SCHEMBL55459) 0.84 2/20
SCHEMBL232936 SCHEMBL232936 0.79 2/20
SCHEMBL233874 SCHEMBL233874 0.79 2/20

Clinical trials — most relevant to CSNK1G2 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
The G Protein-Coupled Receptor Kinase Type 2 Inhibitor Paroxetine as Adjunctive Therapy to Improve Insulin Sensitivity in Patients With Type 2 Diabetes Mellitus PHASE3UNKNOWN
Treatment With HMG-COA Reductase Inhibitor of Growth and Bone Abnormalities in Children With Noonan Syndrome PHASE3COMPLETED
Study to Understand the Genetics of the Acute Response to Metformin and Glipizide in Humans PHASE1COMPLETED
Safety and Tolerability Study of TAK-165 in Subjects With Tumors Expressing HER2 PHASE1COMPLETED
Ad/HER2/Neu Dendritic Cell Cancer Vaccine Testing PHASE1COMPLETED
Identification of Novel Targetable Kinases in SR-a GvHD nanCOMPLETED
Study of Metabolic Modifications in Children With Noonan Syndrome nanCOMPLETED
Nuclear Myosin VI - a Therapeutic Target in Breast Cancer nanUNKNOWN
Muscle Tissue Bank for Muscular Dystrophy nanCOMPLETED
Signs and Symptoms of Genetic Abnormalities Linked to Inherited Heart Disease nanCOMPLETED
Genetics and Psychopathology in the 22q11 Deletion Syndrome nanUNKNOWN
Determining the Association of Chromosomal Variants With Non-PV Triggers and Ablation-outcome in AF (DECAF) nanCOMPLETED
Genetic Markers of CHD Risk in Men and Women nanCOMPLETED
Genetic Investigations in Children With Developmental and Epileptic Encephalopathies in Ho Chi Minh City, Vietnam nanUNKNOWN
Understanding Evidence-Based Practice Patterns in Advanced NSCLC nanCOMPLETED
Family Blood Pressure Program - GenNet Network nanCOMPLETED
Study of a Candidate Gene Involved in Goldenhar Syndrome. nanCOMPLETED
Classification, Functional Stratification and Biomarkers in Ciliopathy (CILLICORIRCM) nanCOMPLETED
Genetic Association of Diabetic Retinopathy-1 nanUNKNOWN
Familial Investigations of Childhood Cancer Predisposition nanRECRUITING
Study on Potential Biomarkers Associated With Clinical Phenotype of EGFR-TKIs in No-small Cell Lung Cancer in China nanUNKNOWN
JAK-STAT Signalling Pathway in Familial Myeloproliferative Disorders nanCOMPLETED
Investigation of the Genetic Causes of Kallmann Syndrome and Reproductive Disorders nanCOMPLETED
Family Blood Pressure Program - SAPPHIRe Network nanCOMPLETED
Ruxolitinib in Patients With Myelofibrosis nanUNKNOWN
Family Blood Pressure Program - HyperGEN nanCOMPLETED
Signs and Symptoms Associated With Molecular Defects in Genetically Inherited Heart Disease nanCOMPLETED
Corpus Callosum Agenesis and Intellectual Disability nanCOMPLETED
The Relation of Microtubule-Associated Protein 2 and Cell Migration nanUNKNOWN
New Genes Involved in Molecular Etiology of Rett Syndrome Through DNA Microarray Comparative Genomic Hybridization nanCOMPLETED

Related proteins — ESM-2 sequence neighbours (a CSNK1G2 binder may also engage these)

ProteinNameSimilarity
Q62762 — 1.000 Q62762 →
Q8BVP5 — 1.000 Q8BVP5 →
Q62761 — 1.000 Q62761 →
Q8C4X2 — 1.000 Q8C4X2 →
Q8BTH8 — 1.000 Q8BTH8 →
CSNK1G1 Casein kinase I isoform gamma-1 1.000 landscape →
Q5PRD4 — 1.000 Q5PRD4 →
Q5ZJS0 — 1.000 Q5ZJS0 →
Q6NRT0 — 0.998 Q6NRT0 →
CSNK1G3 Casein kinase I isoform gamma-3 0.997 landscape →
Q4R9A9 — 0.996 Q4R9A9 →
Q5R4V3 — 0.996 Q5R4V3 →
Q62763 — 0.995 Q62763 →
A7E3X2 — 0.995 A7E3X2 →
Q39050 — 0.995 Q39050 →
A0A0E0S0W9 — 0.993 A0A0E0S0W9 →
Q93Z18 — 0.992 Q93Z18 →
P40236 — 0.992 P40236 →
Q9ZUP4 — 0.992 Q9ZUP4 →
CSNK1E Casein kinase I isoform epsilon 0.992 landscape →
Q5RC72 — 0.991 Q5RC72 →
Q6P3K7 — 0.991 Q6P3K7 →
Q5ZLL1 — 0.990 Q5ZLL1 →
Q8WQ99 — 0.990 Q8WQ99 →
A0A0J9UVX2 — 0.990 A0A0J9UVX2 →
Q7T2E3 — 0.990 Q7T2E3 →
P35508 — 0.990 P35508 →
CSNK1D Casein kinase I isoform delta 0.990 landscape →
P40233 — 0.989 P40233 →
Q6P647 — 0.989 Q6P647 →